Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0537 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0537 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0537 | 0.5 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0537 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0537 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0537 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0537 | 0.5 | 0.5 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0537 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0537 | 0.5 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0537 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0537 | 0.5 | 0.5 |
Plasmodium vivax | RNA helicase-1, putative | 0.0537 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0537 | 0.5 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0537 | 0.5 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0537 | 0.5 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0537 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0537 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0537 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0537 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0537 | 0.5 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0537 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0537 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0537 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | = 0.123 uM | Cytotoxicity against human RPMI8226 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.129 uM | Cytotoxicity against human KM12 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.158 uM | Cytotoxicity against human K562 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.191 uM | Cytotoxicity against human SW620 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.339 uM | Cytotoxicity against human HCT116 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.562 uM | Cytotoxicity against human HL60 (TB) cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.45 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | > 2.63 uM | Cytotoxicity against human NCI49 cell lines | ChEMBL. | 16996657 |
IC50 (ADMET) | = 6.84 uM | Cytotoxicity against human CEM cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 8.42 uM | Cytotoxicity against human Molt4/C8 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 22.9 uM | Cytotoxicity against human COLO205 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 222 uM | Cytotoxicity against human mouse L1210 cells | ChEMBL. | 16996657 |
LogP | = 4.64 | Lipophilicity, log P of the compound | ChEMBL. | 18513966 |
pKa | = 8.5 | Dissociation constant, pKa of the compound | ChEMBL. | 18513966 |
Ratio (binding) | = 48.5 | Reversal of P-glycoprotein-mediated multidrug resistance in human MDR1 gene transfected mouse L5178Y cells assessed as fluorescence activity ratio at 4 ug/ml by flow cytometry | ChEMBL. | 18513966 |
Ratio (binding) | = 63.3 | Reversal of P-glycoprotein-mediated multidrug resistance in human MDR1 gene transfected mouse L5178Y cells assessed as fluorescence activity ratio at 40 ug/ml by flow cytometry | ChEMBL. | 18513966 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.